Liraglutide Promotes Osteoblastic Differentiation in MC3T3-E1 Cells by ERK5 Pathway

Figure 6

Liraglutide-activated ERK5 signaling pathway protein expression. MC3T3-E1 cells were treated with different concentrations of liraglutide for 48 h, and then the protein expression of MEK5, NUR77, ERK5, and p-ERK5 was measured by western blot (a, d). Quantitative analysis of the protein level of MEK5 (b), NUR77 (c), and p-ERK5 (e) in MC3T3-E1 cells after treatment with liraglutide for 48 h.  < 0.01 compared with 0 nM,  < 0.01 compared with 10 nM, and  < 0.01 compared with 100 nM.

(a)

(b)

(c)

(d)

(e)